Managing Major Long-Term Complications Post-Allogeneic HCT
Both malignant and non-malignant blood and bone marrow diseases can be treated with allogeneic hematopoietic cell transplantation (HCT), but the procedure is not without its risks of complications, including the potential for acute or chronic graft-versus-host disease (GVHD). What strategies can be used to recognize symptoms and best manage patients after allogeneic HCT? Our host, Dr. Dennis Kim, takes a deep look into this topic with Dr. Mahmoud Elsawy, Hematologist with the Nova Scotia Health Authority and Clinical Assistant Professor at Dalhousie University. This episode discusses the early- and late-term complications associated with allogeneic HCT and the importance of intervening early and effectively, especially with harder-to-treat phenotypes of GVHD. Our experts also discuss strategies for mitigating the risks of secondary solid tumours and recurrence of primary hematological disease in patients who have undergone allogeneic HCT. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Dennis Kim: Direct financial relationship including receipt of honoraria: Novartis, Sanofi, Pfizer, Jazz, Paladin. Membership on advisory boards or speakers’ bureaus: Novartis, Sanofi, Jazz, Paladin. Funded grants, research or clinical trials: Novartis, Sanofi, Pfizer, Paladin. Dr. Mahmoud Elsawy: Direct financial relationship including receipt of honoraria: AbbVie, Sanofi, Kite, Novartis, BMS, Janssen. Membership on advisory boards or speakers’ bureaus: AbbVie, Sanofi, Kite, Novartis, BMS, Janssen. MAT-CA-2301328 App Sept 2023
